EmanuelE.J., Young-XuY., AshA., GazelleG., NormanLevinsky, MoskowitzM.: How much chemotherapy are cancer patients receiving at the end of life?Proc ASCO, abst 953, 2001.
2.
Aragon-ChingJ.B., CohnJ.B., CohnA.: Chemotherapy at the end of life.Proc ASCO, abst 3119, 2003.
3.
EmanuelE.J., XuY.Y., LevinskyN.G., GazelleG., SayninaO., AshA.S.: Chemotherapy use among medicare beneficiaries at the end of life.Ann Intern Med,18: 639–643, 2003.
4.
EarleC.C., NevilleB.A., LandrumM.B., AyanianJ.Z., BlockS.D., WeeksJ.C.: Trends in the aggressiveness of cancer care near the end of life.J Clin Oncol,22: 315–321, 2004.
5.
AgrawalM., EmanuelE.J.: Ethics of phase I oncology studies: reexamining the arguments and data.JAMA,290: 1075–1082, 2003.
6.
JirilloA., StefaniM., MonfardiniS.: La decisione terapeutica in oncologia medica.Recenti Prog Med,93: 351–354, 2002.
7.
PassalacquaR., CampioneF., CaminitiC., SalvagniS., BarilliA., BellaM., BarniS., BarsantiG., CaffoO., CarliniP., CinquemaniG., Di CostanzoF., GiustiniL., LabiancaR., MazzeiA., OlmeoN., PaccagnellaA., ToscanoL., CocconiG.: Patients’ opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy.Lancet,353: 1310–1314, 1999.
8.
MonfardiniS., JirilloA., BoscaroM., GaleazzoM., PitocchiO.: Can the ISO 9000 quality assessment be applied to the practice of medical oncology?Ann Oncol,14: 1795, 2003.
9.
EarleC.C., ParkE.R., LaiB., WeeksJ.C., AyanianJ.C., BlockS.: Identifying potential indicators of the quality of end-of-life cancer care from administrative data.J Clin Oncol,21: 1133–1138, 2003.
